Teladoc Health (NYSE:TDOC) Given Hold Rating at Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Teladoc Health (NYSE:TDOC - Free Report) in a report issued on Friday, Benzinga reports.

Other equities analysts have also recently issued research reports about the company. Truist Financial cut their price objective on Teladoc Health from $23.00 to $17.00 and set a hold rating on the stock in a report on Wednesday, March 6th. Cantor Fitzgerald started coverage on Teladoc Health in a report on Thursday, February 29th. They set an overweight rating and a $22.00 price objective on the stock. Piper Sandler cut their target price on Teladoc Health from $30.00 to $25.00 and set an overweight rating on the stock in a research note on Wednesday, February 21st. Leerink Partnrs restated a market perform rating on shares of Teladoc Health in a research note on Monday, February 26th. Finally, SVB Leerink started coverage on Teladoc Health in a research note on Monday, February 26th. They issued a market perform rating and a $17.00 target price on the stock. Nine analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of Hold and a consensus price target of $22.43.

Teladoc Health Trading Up 1.8 %

TDOC stock traded up $0.25 during midday trading on Friday, reaching $14.50. The stock had a trading volume of 7,655,168 shares, compared to its average volume of 4,719,043. The business has a fifty day simple moving average of $16.91 and a two-hundred day simple moving average of $18.32. The company has a quick ratio of 3.47, a current ratio of 3.54 and a debt-to-equity ratio of 0.66. The firm has a market cap of $2.42 billion, a price-to-earnings ratio of -10.63 and a beta of 0.94. Teladoc Health has a twelve month low of $13.59 and a twelve month high of $30.41.

Teladoc Health (NYSE:TDOC - Get Free Report) last announced its quarterly earnings data on Tuesday, February 20th. The health services provider reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.05. The firm had revenue of $660.50 million during the quarter, compared to analyst estimates of $670.79 million. Teladoc Health had a negative return on equity of 9.22% and a negative net margin of 8.47%. The company's revenue was up 3.6% on a year-over-year basis. During the same period last year, the company earned ($0.23) earnings per share. As a group, research analysts expect that Teladoc Health will post -1.07 EPS for the current fiscal year.

Insider Buying and Selling at Teladoc Health

In other news, CAO Richard J. Napolitano sold 3,765 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $54,667.80. Following the sale, the chief accounting officer now directly owns 18,077 shares of the company's stock, valued at approximately $262,478.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CAO Richard J. Napolitano sold 3,765 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $54,667.80. Following the sale, the chief accounting officer now directly owns 18,077 shares of the company's stock, valued at approximately $262,478.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Laizer Kornwasser sold 7,882 shares of the stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $19.18, for a total value of $151,176.76. Following the sale, the insider now directly owns 57,223 shares in the company, valued at $1,097,537.14. The disclosure for this sale can be found here. Insiders have sold a total of 134,441 shares of company stock valued at $2,025,041 in the last ninety days. 1.63% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Teladoc Health

Large investors have recently bought and sold shares of the company. ARK Investment Management LLC increased its stake in shares of Teladoc Health by 4.5% in the fourth quarter. ARK Investment Management LLC now owns 21,224,565 shares of the health services provider's stock valued at $457,389,000 after buying an additional 912,692 shares during the period. Vanguard Group Inc. grew its stake in Teladoc Health by 11.8% during the fourth quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider's stock worth $377,451,000 after purchasing an additional 1,855,480 shares during the period. Dimensional Fund Advisors LP grew its stake in Teladoc Health by 25.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,834,422 shares of the health services provider's stock worth $82,636,000 after purchasing an additional 767,999 shares during the period. Renaissance Technologies LLC grew its stake in Teladoc Health by 36.6% during the first quarter. Renaissance Technologies LLC now owns 3,369,500 shares of the health services provider's stock worth $87,270,000 after purchasing an additional 902,100 shares during the period. Finally, Two Sigma Investments LP grew its stake in Teladoc Health by 68.6% during the first quarter. Two Sigma Investments LP now owns 3,191,291 shares of the health services provider's stock worth $82,654,000 after purchasing an additional 1,298,934 shares during the period. 76.82% of the stock is currently owned by institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.